Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.21 USD | -0.46% | +0.12% | -19.33% |
05:31pm | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
05-01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.33% | 81.69B | |
+31.13% | 699B | |
+25.07% | 571B | |
-4.27% | 364B | |
+18.35% | 326B | |
+3.31% | 286B | |
+14.38% | 236B | |
+4.60% | 198B | |
-12.60% | 194B | |
-4.53% | 154B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Unit Receives Positive CHMP Opinion for Lymphoblastic Leukemia Treatment in Adults